Muscle-Invasive Bladder Cancer (MIBC) — urothelial carcinoma that has invaded the detrusor muscle of the bladder wall (clinical stage T2 or higher), representing approximately 25% of all bladder cancer diagnoses but accounting for a disproportionate burden of bladder cancer mortality because of its propensity for lymph node metastasis, hematogenous dissemination to lung, liver, and bone, and the surgical morbidity of radical cystectomy with urinary diversion — is the most complex and therapeutically intensive form of bladder cancer management, requiring the coordinated expertise of urologic oncology, medical oncology, radiation oncology, reconstructive urology, and supportive care teams across a multimodal treatment pathway where the sequence, timing, and eligibility assessment for each treatment component directly determines long-term survival outcomes. MIBC management has been transformed by the establishment of neoadjuvant cisplatin-based chemotherapy as a standard-of-care component conferring an approximately 8% absolute overall survival benefit over surgery alone — with dose-dense MVAC (ddMVAC: methotrexate, vinblastine, doxorubicin, cisplatin) and gemcitabine-cisplatin (GC) as the two accepted neoadjuvant regimens — followed by radical cystectomy with urinary diversion (ileal conduit, neobladder, or Indiana pouch), or, in appropriately selected patients, trimodality therapy (TMT) combining maximal transurethral resection of bladder tumor (TURBT), concurrent chemotherapy, and external beam radiation as a bladder-preserving alternative achieving comparable oncologic outcomes to cystectomy in eligible patients. For patients ineligible for cisplatin-based therapy due to renal insufficiency (GFR <60 mL/min/1.73m²), hearing impairment (Grade 2+ audiometric loss), Eastern Cooperative Oncology Group performance status ≥2, or significant comorbidity, pembrolizumab (anti-PD-1 checkpoint inhibitor) has received FDA approval as first-line therapy for cisplatin-ineligible MIBC patients unfit for any platinum, and enfortumab vedotin plus pembrolizumab has become the preferred frontline combination in metastatic disease. FGFR3 alterations (activating mutations or fusions), present in approximately 20% of urothelial carcinomas with enrichment in upper tract and low-grade tumors, confer eligibility for erdafitinib — the first approved FGFR inhibitor for urothelial carcinoma — in platinum-refractory disease with FGFR3/2 alterations detected by molecular profiling. Surgical timing is critical in MIBC management: radical cystectomy performed within 90 days of TURBT has been associated with superior oncologic outcomes compared to delayed surgery, and care technology platforms coordinating the complex logistics of preoperative cisplatin eligibility assessment, neoadjuvant chemotherapy scheduling, surgical booking, and urinary diversion selection must ensure that no component of this time-sensitive pathway is delayed by platform unavailability.
MIBC technology platforms — whether supporting urologic oncology programs coordinating cisplatin eligibility assessment (real-time GFR calculation from serum creatinine and cystatin C; audiometry scheduling and Grade 2+ hearing threshold documentation; ECOG performance status recording; cardiac function assessment for doxorubicin-containing regimens; nephrology consultation records for borderline renal function), medical oncology platforms managing neoadjuvant ddMVAC or GC chemotherapy administration (cycle scheduling aligned to surgical booking timelines; myelosuppression monitoring and G-CSF administration; nephrotoxicity and ototoxicity surveillance; dose modification documentation), surgical logistics platforms coordinating cystectomy timing (TURBT-to-cystectomy interval tracking with 90-day benchmark; OR scheduling for radical cystectomy with ileal conduit or neobladder reconstruction; urostomy nursing consultation records; pelvic rehabilitation referrals), urinary diversion care dashboards (stomal complication monitoring, urostomy output and hydration records, neobladder capacity training documentation, continent diversion catheterization scheduling), and pembrolizumab maintenance scheduling systems post-cystectomy (pembrolizumab adjuvant infusion scheduling, immune-related adverse event monitoring, thyroid function and adrenal function surveillance) — must maintain the availability and performance standards that MIBC's time-sensitive surgical coordination, multiagent chemotherapy toxicity monitoring, and complex urinary reconstruction care demands. This guide explains why MIBC care tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the eligibility assessment, chemotherapy logistics, surgical coordination, and urinary diversion management complexity of modern MIBC care.
Why MIBC Tech Platforms Require Specialized Monitoring Attention
MIBC management is defined by the cisplatin eligibility assessment urgency that determines whether a patient receives the 8% OS survival benefit of neoadjuvant chemotherapy or proceeds directly to cystectomy, the neoadjuvant chemotherapy scheduling precision required to complete 3–4 cycles before cystectomy while maintaining the ≤90-day TURBT-to-surgery benchmark, the surgical coordination complexity of radical cystectomy with urinary diversion in a major pelvic oncologic operation requiring multidisciplinary perioperative coordination, the urinary diversion care intensity of managing stomal complications, neobladder capacity training, and continent diversion catheterization schedules in the postoperative period, and the pembrolizumab immune surveillance intensity of monitoring immune-related adverse events across 12 months of adjuvant checkpoint inhibitor therapy. Technology failures in these domains create disruptions calibrated to the time-sensitive and technically complex nature of MIBC's multimodal treatment pathway.
Cisplatin eligibility assessment platforms determine access to neoadjuvant survival benefit. The eligibility assessment for cisplatin-based neoadjuvant chemotherapy — GFR ≥60 mL/min/1.73m², Grade <2 audiometric threshold, ECOG PS ≤1, adequate cardiac function for doxorubicin in ddMVAC, and absence of peripheral neuropathy — directly determines whether a patient receives the 8% absolute OS benefit of neoadjuvant therapy or is deemed cisplatin-ineligible and proceeds to alternative strategies including pembrolizumab, carboplatin-based regimens, or direct cystectomy. Monitor eligibility assessment platforms at 1-minute intervals during clinical hours.
Neoadjuvant chemotherapy scheduling platforms must maintain the TURBT-to-cystectomy benchmark. ddMVAC and GC neoadjuvant chemotherapy for MIBC requires 3–4 cycles typically delivered over 9–12 weeks before cystectomy, where cycle scheduling must leave adequate time for postchemotherapy recovery before surgery while maintaining the ≤90-day TURBT-to-cystectomy benchmark associated with superior oncologic outcomes. Monitor chemotherapy scheduling platforms at 1-minute intervals during clinical hours.
Surgical logistics platforms coordinate the most complex pelvic oncologic operation in urology. Radical cystectomy with ileal conduit or neobladder reconstruction is one of the most technically demanding operations in urologic oncology, requiring OR scheduling, bowel preparation coordination, urostomy nurse consultation, pelvic rehabilitation referral, reconstructive urology planning for neobladder vs. conduit decision, and postoperative intensive care coordination — all within a time-sensitive window where delays beyond 90 days from TURBT are associated with worse oncologic outcomes. Monitor surgical logistics platforms at 1-minute intervals during operative and perioperative periods.
Urinary diversion care dashboards manage complex postoperative surveillance. Urinary diversion complications — stomal stenosis, pyelonephritis, urostomy skin complications, urinary tract infections requiring antibiotic management, neobladder voiding dysfunction requiring intermittent catheterization, and continent diversion catheterization scheduling — require platforms managing real-time urostomy output monitoring, culture result integration, stoma care nursing documentation, and neobladder training schedules across the months of postoperative recovery. Monitor urinary diversion platforms during clinical hours with sustained-failure alerting.
Pembrolizumab maintenance platforms manage immune-related adverse event surveillance. Adjuvant pembrolizumab post-cystectomy requires immune-related adverse event (irAE) surveillance across 12 months of maintenance therapy — thyroid function monitoring for immune-mediated thyroiditis, adrenal function for immune-mediated adrenal insufficiency, transaminase monitoring for immune-mediated hepatitis, creatinine monitoring for immune-mediated nephritis, and pulmonary function assessment for immune-mediated pneumonitis — requiring integrated oncology platforms that connect immunotherapy administration records with toxicity surveillance dashboards. Monitor pembrolizumab platforms at 1-minute intervals during infusion sessions.
What to Monitor on a MIBC Tech Platform
Cisplatin Eligibility Assessment
Monitor GFR calculation platforms integrating serum creatinine, cystatin C, and demographic data for real-time cisplatin eligibility determination; audiometry scheduling and Grade 2+ hearing threshold documentation platforms; ECOG performance status recording and oncology assessment documentation; cardiac function assessment (echocardiography or MUGA) records for doxorubicin eligibility in ddMVAC regimens; nephrology consultation records for borderline GFR 50–60 mL/min cases considering split-dose cisplatin eligibility; and oncology tumor board documentation for cisplatin eligibility determination at 1-minute intervals during clinical hours. Alert immediately — eligibility assessment platform failures delay the determination of whether a patient receives the 8% OS survival benefit of neoadjuvant cisplatin-based chemotherapy, with each week of delay compressing the available neoadjuvant treatment window before the ≤90-day surgical benchmark.
Neoadjuvant Chemotherapy Administration
Monitor ddMVAC chemotherapy prescribing and administration records (methotrexate, vinblastine, doxorubicin, cisplatin cycle documentation; pegfilgrastim administration records; dose modification documentation); GC chemotherapy administration records (gemcitabine and cisplatin cycle scheduling, nephrotoxicity monitoring, dose delays for renal function); cisplatin pre-hydration and post-hydration volume documentation; antiemetic protocol administration records; cycle completion and delay documentation; and oncology pharmacy preparation and verification records at 1-minute intervals during infusion sessions. Alert immediately — chemotherapy administration platform failures during active cisplatin infusion disrupt the infusion nursing workflow and toxicity documentation in a patient receiving definitive neoadjuvant therapy where cycle delays compress the pre-surgical chemotherapy completion window.
Neoadjuvant Chemotherapy Toxicity Monitoring
Monitor nephrotoxicity surveillance platforms (serial creatinine and GFR trends across cisplatin cycles, dose modification thresholds, nephrology referral triggers); ototoxicity monitoring (serial audiometry linked to cumulative cisplatin dose, Grade 2+ threshold triggers for therapy modification); myelosuppression dashboards (ANC nadir tracking, G-CSF administration documentation, transfusion records for anemia and thrombocytopenia); mucositis and neuropathy assessment records for cumulative methotrexate and cisplatin toxicity; and ddMVAC febrile neutropenia management records with G-CSF and antibiotic protocol documentation during clinical hours. Alert on sustained failures — toxicity monitoring platform unavailability delays detection of cisplatin nephrotoxicity or ototoxicity requiring dose modification before the next chemotherapy cycle.
Surgical Logistics and Cystectomy Coordination
Monitor TURBT procedure date recording and TURBT-to-cystectomy interval calculation dashboards with 90-day benchmark tracking; OR scheduling platforms for radical cystectomy with urinary diversion; urostomy nursing consultation and patient education documentation; pelvic rehabilitation referral records; reconstructive urology platform records for neobladder, ileal conduit, and Indiana pouch decision documentation; anesthesia pre-assessment records for major pelvic surgery; blood bank and coagulation pre-operative preparation records; and postoperative ICU or step-down unit admission documentation at 1-minute intervals during perioperative periods. Alert immediately — surgical logistics platform failures during cystectomy planning and coordination disrupt the multidisciplinary perioperative team's coordination of a major pelvic oncologic operation where scheduling delays risk exceeding the 90-day TURBT-to-cystectomy benchmark.
Urinary Diversion Care Dashboards
Monitor stomal complication surveillance platforms (stomal stenosis, parastomal hernia, skin complication documentation); urostomy output and hydration monitoring records; culture and sensitivity results for urinary tract infections and pyelonephritis management; urostomy appliance and stoma care nursing documentation; neobladder voiding dysfunction assessment and intermittent catheterization scheduling platforms; continent diversion (Indiana pouch) catheterization interval scheduling and complication documentation; and long-term upper tract surveillance (renal ultrasound, serum creatinine) scheduling during clinical hours. Alert on sustained failures — urinary diversion care platform failures delay stomal complication detection, infection management, and neobladder training coordination in patients dependent on these systems for basic urinary function management.
FGFR3 Molecular Testing and Erdafitinib Management
Monitor molecular profiling platforms for FGFR3 mutation and fusion detection (next-generation sequencing or targeted FGFR3 hotspot panels); FGFR2/3 fusion assay documentation; erdafitinib prescribing and pharmacy verification for FGFR3-altered platinum-refractory disease; erdafitinib dose titration records based on serum phosphate levels (pharmacodynamic surrogate); ophthalmology surveillance records for central serous retinopathy (a class-effect toxicity of FGFR inhibitors); and hyperphosphatemia management records (dietary phosphate restriction, phosphate binders) during business hours. Alert on sustained failures — FGFR3 molecular testing platform failures delay erdafitinib eligibility determination in platinum-refractory patients with FGFR3-altered urothelial carcinoma.
Pembrolizumab Maintenance and Immune Surveillance
Monitor pembrolizumab adjuvant infusion administration records and scheduling platforms; thyroid function monitoring (TSH, free T4) documentation for immune-mediated thyroiditis; adrenal function (AM cortisol, ACTH) records for immune-mediated adrenal insufficiency; transaminase monitoring (ALT, AST) for immune-mediated hepatitis; creatinine surveillance for immune-mediated nephritis; pulmonary symptom assessment and CT chest records for immune-mediated pneumonitis; corticosteroid management records for Grade 3–4 irAE requiring pembrolizumab hold and systemic steroid therapy; and pembrolizumab completion or discontinuation documentation across 12 months of maintenance therapy during business and infusion hours. Alert on sustained failures — pembrolizumab surveillance platform failures delay immune-related adverse event detection in patients receiving checkpoint inhibitor maintenance where undetected Grade 3–4 irAE require urgent steroid therapy.
Trimodality Therapy (TMT) Coordination
Monitor TURBT maximal resection documentation for TMT eligibility assessment; radiation oncology treatment planning platforms (external beam RT target volume delineation, dose-volume histograms, bladder and rectal dose constraints); radiosensitizing chemotherapy administration records for concurrent cisplatin or gemcitabine during RT; cystoscopic re-evaluation documentation post-induction TMT for complete response assessment; consolidation RT treatment delivery records; and long-term bladder preservation surveillance (cystoscopy and urine cytology scheduling) during treatment and business hours. Alert on sustained failures — TMT coordination platform failures disrupt the RT-chemotherapy schedule integration and cystoscopic response assessment that determines whether TMT consolidation can proceed with bladder preservation.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. MIBC programs coordinate across urologic oncology, medical oncology, radiation oncology, reconstructive urology, stoma therapy nursing, nephrology, audiology, and supportive oncology — authentication failures simultaneously block every member of the multidisciplinary MIBC team managing a patient whose cisplatin eligibility assessment, neoadjuvant chemotherapy, surgical coordination, urinary diversion care, and pembrolizumab surveillance all require continuous, coordinated platform access.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, oncology infusion systems, surgical planning platforms, radiation therapy systems, urinary diversion care platforms, and pembrolizumab maintenance tracking systems. Certificate errors disrupt the eligibility assessment, chemotherapy scheduling, and surgical coordination workflows critical to MIBC's time-sensitive multimodal management.
HIPAA and Oncology Data Privacy Considerations
MIBC technology platforms handle sensitive PHI including cisplatin eligibility assessment records with GFR, audiometry, and cardiac function results, neoadjuvant chemotherapy administration and toxicity documentation, operative records for radical cystectomy with urinary diversion (a major pelvic operation with profound urinary and sexual function implications), urinary diversion care records (stomal output, pyelonephritis, continence status) spanning years of post-cystectomy surveillance, FGFR3 molecular profiling results with targeted therapy eligibility implications, and pembrolizumab immune-related adverse event records. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI.
For platforms managing urinary diversion care records and neobladder function documentation — where records of urinary continence status, catheterization dependence, stomal management, and sexual function after cystectomy reflect profoundly personal functional consequences with implications for employment, insurance, and quality of life — privacy and availability standards must reflect the sensitivity of combined oncologic and functional PHI managed across years of post-cystectomy surveillance. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for MIBC programs managing the convergent eligibility, chemotherapy, surgical, urinary diversion, and immunotherapy PHI streams of bladder cancer care.
Alerting Strategy for MIBC Tech Platforms
Immediate alerting during infusion sessions: Neoadjuvant ddMVAC and GC chemotherapy administration platforms, cisplatin pre-hydration and toxicity monitoring, pembrolizumab infusion administration, and radiosensitizing chemotherapy during concurrent TMT chemoradiation. These cannot fail during infusion without direct patient safety and documentation consequence.
Immediate alerting during operative periods: Surgical logistics platforms, OR scheduling, urostomy nurse consultation, anesthesia pre-assessment, and postoperative ICU coordination during radical cystectomy perioperative periods.
Immediate business-hours alert: Cisplatin eligibility assessment platforms (GFR/audiometry/ECOG), TURBT-to-cystectomy interval tracking dashboards, neoadjuvant toxicity monitoring dashboards, and FGFR3 molecular profiling platforms. Alert the moment these fail during active clinical encounters.
Sustained-failure alert (10–15 minutes): Urinary diversion care dashboards, pembrolizumab irAE surveillance, TMT response assessment, long-term bladder preservation surveillance, and MIBC tumor board documentation platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms MIBC platform availability from geographies where high-volume cystectomy centers with dedicated urinary diversion programs concentrate — important for platforms supporting patients traveling to centers where neobladder reconstruction and continent diversion expertise reduces stomal complication rates relative to regional institutions.
Status Page for MIBC Care Team Communication
A real-time status page gives urologic oncologists coordinating neoadjuvant chemotherapy and cystectomy logistics, medical oncologists managing ddMVAC and GC toxicity, radiation oncologists delivering TMT chemoradiation, stoma therapy nurses managing urinary diversion complications, and pembrolizumab surveillance teams monitoring irAEs immediate platform visibility without requiring inbound IT support contact. During a surgical logistics platform outage when the urologic oncology team must confirm the TURBT-to-cystectomy interval before booking OR time for a patient who completed neoadjuvant GC — and where exceeding 90 days from TURBT without surgical booking requires escalation to the multidisciplinary team for urgency reassessment — a status page enables immediate contingency protocol activation ensuring manual interval calculation and OR booking through administrative fallback channels without platform-dependent delay.
Include the status page URL in neoadjuvant chemotherapy scheduling downtime procedures, surgical logistics emergency coordination protocols, urinary diversion care fallback workflows, and pembrolizumab irAE management contingency plans.
Vigilmon Setup for MIBC Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Cisplatin eligibility assessment (GFR / audiometry / ECOG) | 1 min | Slack + PagerDuty (clinical hours) | | TURBT-to-cystectomy interval tracking (90-day benchmark) | 1 min | Slack + PagerDuty (clinical hours) | | Neoadjuvant ddMVAC / GC chemotherapy administration | 1 min | Slack + PagerDuty (infusion hours) | | Cisplatin nephrotoxicity / ototoxicity monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Surgical logistics / OR scheduling / urostomy nursing | 1 min | Slack + PagerDuty (operative hours) | | Pembrolizumab infusion administration | 1 min | Slack + PagerDuty (infusion hours) | | Pembrolizumab irAE surveillance (thyroid / adrenal / hepatic) | 2 min | Slack + PagerDuty (business hours) | | FGFR3 molecular profiling and erdafitinib management | 2 min | Slack (business hours) | | Urinary diversion care dashboards | 2 min | Slack (business + clinical hours) | | TMT chemoradiation coordination | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure cisplatin eligibility assessment platforms (GFR, audiometry, ECOG, cardiac function) with immediate clinical-hours alerting
- Add TURBT-to-cystectomy interval tracking dashboards with immediate alerting against the 90-day benchmark
- Configure neoadjuvant ddMVAC and GC chemotherapy administration with immediate infusion-hours alerting
- Add cisplatin nephrotoxicity and ototoxicity monitoring platforms with immediate clinical-hours alerting
- Configure surgical logistics, OR scheduling, and urostomy nursing consultation with immediate operative-hours alerting
- Add pembrolizumab infusion administration with immediate infusion-hours alerting
- Configure pembrolizumab irAE surveillance (thyroid, adrenal, hepatic, renal, pulmonary) with sustained-failure alerting
- Add FGFR3 molecular profiling and erdafitinib management platforms with sustained-failure alerting
- Configure urinary diversion care dashboards with sustained-failure alerting
- Add TMT chemoradiation coordination platforms with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, surgical, radiation, pharmacy, and surveillance domains
- Add the status page URL to neoadjuvant chemotherapy downtime procedures, surgical coordination emergency protocols, and urinary diversion care fallback workflows
Conclusion
MIBC technology platforms are embedded in clinical decisions where cisplatin eligibility assessment platform availability in the period after TURBT diagnosis — where the urologic oncologist must determine whether a patient with GFR of 58 mL/min and borderline audiometric thresholds qualifies for the 8% OS benefit of neoadjuvant cisplatin-based chemotherapy, where the nephrology consultation records from the prior week's GFR measurement and the audiometry report from the otolaryngology appointment must be simultaneously accessible in the platform for the eligibility decision to be made, where the medical oncologist planning the ddMVAC schedule must confirm that 3 cycles can be completed before the 90-day TURBT-to-cystectomy benchmark, and where a cisplatin eligibility determination delayed by platform unavailability means either forgoing neoadjuvant therapy or allowing the TURBT-to-cystectomy interval to drift past the 90-day benchmark associated with inferior oncologic outcomes — cannot be interrupted by platform outage at the precise moment when the eligibility determination gates the entire downstream treatment pathway; where neoadjuvant chemotherapy administration platform availability during an active cisplatin infusion in week 8 of a 12-week ddMVAC course — where the infusion nurse documenting the cisplatin infusion start time, the pre-hydration completion volume, and the magnesium sulfate administration must access the chemotherapy administration platform to verify the cycle number and dose, where the oncologist must confirm that this morning's creatinine of 1.3 mg/dL (GFR 54) is below the threshold requiring cisplatin dose reduction and that the audiometry from last cycle showed Grade 1 threshold shift not reaching the Grade 2 modification threshold, and where the surgical team must confirm that the planned OR date 3 weeks from today still allows adequate surgical recovery time — cannot be delayed by platform unavailability when the patient is already in the infusion chair with IV access established; and where urinary diversion care platform availability during a post-cystectomy stomal complication assessment — where a patient with an ileal conduit 6 weeks post-cystectomy presents with peristomal skin breakdown and urostomy bag seal failure requiring stoma care nursing consultation, wound care product ordering, and appliance fitting adjustment documentation in the platform — determines whether this patient's stomal complication is managed with the documentation continuity that prevents recurrence and that supports the long-term surveillance of stomal function that is fundamental to the quality of life of every patient living with a urinary diversion. A cisplatin eligibility platform that fails when the oncologist must make the treatment-determining eligibility call within the TURBT-to-cystectomy window, a surgical logistics platform inaccessible when OR scheduling for cystectomy must be confirmed before the 90-day benchmark expires, a urinary diversion care dashboard unavailable when the stoma care nurse must document a stomal stenosis requiring dilation — these are not IT incidents. They are clinical disruptions in the management of a life-threatening malignancy whose multimodal treatment pathway is defined by time-sensitive benchmarks, chemotherapy coordination complexity, and long-term urinary reconstruction management that demand continuous platform availability at every step.
Uptime monitoring gives MIBC tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to urologic oncology programs, oncology pharmacy, radiation oncology departments, and compliance auditors that platform operational reliability matches the eligibility assessment urgency, chemotherapy scheduling precision, surgical coordination demands, and urinary diversion care intensity of modern MIBC management.
Start monitoring your MIBC care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #MIBC #bladdercancer #muscleinvasive #cystectomy #ddMVAC #gemcitabinecisplatin #neoadjuvant #urostomy #neobladder #urinarydiversion #pembrolizumab #FGFR3 #erdafitinib #trimodalitytherapy #cisplatineligibility #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre